Back to search results
NCT05509998

Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication

Enrolling by Invitation
NAAges 12–30InterventionalHealth services
Icahn School of Medicine at Mount Sinai
~912 participants
Updated 2025-07-20 on ClinicalTrials.gov
What's tested:Screening Method (SM)Screening and Communication Method (SCM)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Duration of untreated psychosis (DUP)
Measured over up to 2 years

Conditions

First Episode Psychosis (FEP)
Clinical High Risk for Psychosis (CHR)

Explore related trials

Clinical High Risk for PsychosisFirst Episode Psychosis

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Yulia Landa, PsyD, MS · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

age 12- 30
ability to participate in assessments in English or Spanish
ability to provide informed consent (assent for those under age 18)

Exclusion

previous diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, or delusional disorder.

What this trial measures

  • Duration of untreated psychosis (DUP)up to 2 years

    The DUP is defined as the time, in weeks, between onset of psychotic symptoms (measured by the Symptom Onset in Schizophrenia Scale) and initiation of FEP treatment (date of intake into Coordinated Specialty Care (CSC) programs for first episode psychosis.